Wanbury Achieves USFDA Milestones and Expands Global Metformin Business
Wanbury Ltd 路 Press Release 路 16 Oct 2026, 6:42 pm
Wanbury Achieves USFDA Milestones and Expands Global Metformin Business Wanbury received nine "No DMF Deficiency" letters from the USFDA across Jul鈥揂ug'26 for Metformin HCl, alongside approvals for Paroxetine and Diphenhydramine HCl. Expanding its API pipeline, the company is validating Quetiapine Fumarate, Sitagliptin, and Empagliflozin, with regulatory filings planned next quarter for semi-regulated markets. In commercial expansions, Wanbury commercialised a Metformin DC business in Saudi Arabia with an annual revenue potential of ~Rs 10 crore, while its customer secured a two-year Metformin supply tender in Mexico valued at ~Rs 15 crore per annum.
Original exchange filing (PDF)
More announcements from Wanbury Ltd
- Disclosure under Regulation 30 of the SEBI LODR, 2015 - Investors Presentation on Q2 and Half Year ended 30.09.2026. 路 18 Nov 2026
- Clarifications on investor queries regarding recent announcement 路 16 Nov 2026
- Wanbury Limited''s Tanuku Plant - US FDA Inspection - Updates 路 16 Nov 2026
- Wanbury Limited received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil FDA) for its flagship product Metformin HC1 EP grade. 路 12 Nov 2026
- Press Release on Standalone and Consolidated Un-audited Financial Results for the second quarter & half year ended 30th September, 2026. 路 06 Nov 2026
- Financial Results as on 30th September, 2026 路 05 Nov 2026
- Outcome of the Board Meeting held on November 04, 2026 路 05 Nov 2026
- Wanbury Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 05 Nov 2026
